“`html
Dapirolizumab pegol (DZP) has shown significant efficacy in reducing fatigue and disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE) during the Phase 3 PHOENYCS GO study. At Week 48, 40.9% of participants receiving DZP achieved low disease activity, compared to 19.6% with standard care. Improvements in fatigue were evident as early as Week 12 using various assessment measures.
While these results indicate DZP’s potential to meet critical unmet needs in SLE treatment, the drug is not yet approved and its safety and efficacy have not been established. A second Phase 3 trial is currently ongoing to confirm these preliminary findings.
The study results were presented at EULAR 2025 in Barcelona, Spain, highlighting the importance of addressing fatigue in SLE management, a condition that primarily affects women and can significantly impair quality of life.
“`
